

**APTIL PHARMA LIMITED**

**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 MARCH 2019**

	<b>Year ended 31.3.19 £</b>	<b>Year ended 31.3.18 £</b>
<b>CONTINUING OPERATIONS</b>		
Administrative expenses	-	(148,491)
<b>OPERATING LOSS</b>	-	(148,491)
Profit on transfer of trade and assets to parent company	-	1,554,690
<b>PROFIT/(LOSS) BEFORE INCOME TAX</b>	-	(1,406,199)
Income tax	-	-
<b>PROFIT/(LOSS) FOR THE YEAR</b>	-	1,406,199
<b>OTHER COMPREHENSIVE INCOME</b>	-	-
<b>TOTAL COMPREHENSIVE INCOME FOR THE YEAR</b>	-	1,406,199

STATEMENT OF FINANCIAL POSITION 31 MARCH 2019

	Note	2019 £	2018 £
<b>ASSETS</b>			
<b>CURRENT ASSETS</b>			
Trade and other receivables	3	1	1
<b>TOTAL ASSETS</b>		<u>1</u>	<u>1</u>
<b>EQUITY</b>			
<b>SHAREHOLDERS' EQUITY</b>			
Called up share capital	4	1	1
<b>TOTAL EQUITY</b>		<u>1</u>	<u>1</u>

For the year ended 31<sup>st</sup> March 2019, the company was entitled to exemption from audit under section 480 of the Companies Act 2006.

Members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Board of Directors on 08/05/2019 and were signed on its behalf by:

  
 .....  
 Jamie Durbidge - Director

Date: 08/05/2019

**APTIL PHARMA LIMITED**

**STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 MARCH 2019**

	<b>Called up share capital £</b>	<b>Retained earnings £</b>	<b>Total equity £</b>
<b>Balance at 31 March 2017</b>	<u>1</u>	<u>(1,406,199)</u>	<u>(1,406,198)</u>
<b>Changes in equity</b>			
Total comprehensive income		1,406,199	1,406,199
<b>Balance at 31 March 2018</b>	<u>1</u>	<u>-</u>	<u>1</u>
<b>Changes in equity</b>			
Total comprehensive income		-	-
<b>Balance at 31 March 2019</b>	<u>1</u>	<u>-</u>	<u>1</u>

## APTIL PHARMA LIMITED

### NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2019

#### 1. ACCOUNTING POLICIES

##### Basis of preparation

Aptil Pharma Limited (the "Company") is a private company incorporated, domiciled and registered in England in the UK. The company financial statements have been prepared and approved by the directors in accordance with International Financial Reporting Standards as adopted by the EU ("Adopted IFRSs"). The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements. The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies.

#### 2. EMPLOYEES AND DIRECTORS

There were no staff costs for the year ended 31 March 2019 nor for the year ended 31 March 2018. Directors are not remunerated for their services. The average monthly number of employees during the year was as follows:

	Year ended 31.3.19	Year ended 31.3.18
Directors	<u>4</u>	<u>4</u>
	£	£
Directors' remuneration	<u>-</u>	<u>-</u>

#### 3. TRADE AND OTHER RECEIVABLES

	Year ended 31.3.19	Year ended 31.3.18
	£	£
Trade and other receivables	<u>1</u>	<u>1</u>

#### 4. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:

Number: value:	Class:	Nominal	2019 £	2018 £
1	Ordinary	£1	1	1

The notes form part of these financial statements

**5. ULTIMATE PARENT COMPANY AND PARENT COMPANY OF THE LARGER GROUP**

The parent company is Torrent Pharma UK Ltd, who owns 100% shareholding of Aptil Pharma Limited. Torrent Pharma UK Ltd is a subsidiary undertaking of Torrent Pharmaceuticals Limited which is the ultimate parent company incorporated in India. The ultimate controlling party is Torrent Private Ltd which owns the controlling stake in Torrent Pharmaceuticals Limited.

The largest group in which the result of the Company is consolidated is that headed by Torrent Pharmaceuticals Limited, registered office at Off. Ashram Road, Ahmedabad- 380 009, Gujarat, India. The consolidated financial statements of these group are available to the public and may be obtained from the registered office.

**6. RELATED PARTY DISCLOSURES**

**1. Parent Company:**

**Torrent Pharma (UK) LTD:** NIL

**2. Group Companies:**

**Torrent Pharma GmbH**  
Expenses charged by group company in the year: NIL (2018: £11,213)

**7. JUDGEMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY**

Preparation of the financial statements does not require management to make significant judgements and estimates.